Eli Lilly Reports Kinsula (Donanemab-Azbt) Approval in China to Treat Early Symptomatic Alzheimer's Disease
Shots:
- The NMPA has approved Kisunla (donanemab-azbt) based on P-III (TRAILBLAZER-ALZ 2) study to treat early symptomatic Alzheimer's disease (incl. MCI & mild dementia) in patients (n=1736)
- The study assessed Kisunla vs PBO in 2 patient groups: group 1 with low-to-medium tau levels & group 2 of the overall population (incl. high tau levels), showing a 35% & 22% decline on iADRS, respectively, & reducing disease progression risk by 39%
- In group 2, amyloid plaques were reduced by 61% at 6mos., 80% at 12mos., & 84% at 18mos. during treatment. 66% of patients achieved minimal amyloid plaque levels within 1 year, consistent with a visually negative PET scan, switching to PBO thereafter. Data was published in the JAMA
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Reports the CHMP’s Positive Opinion of Omvoh (Mirikizumab) to Treat Moderate to Severe Active Crohn's Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
